Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR study) Submitted by amarin on Fri, 09/27/2019 - 19:40 Home Read more about Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR study)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia Submitted by amarin on Fri, 09/27/2019 - 19:04 Home Read more about Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
REDUCE-IT: Residual Cardiovascular Risk in Statin-Treated Patients with Elevated Triglycerides: Now We Can REDUCE-IT! Submitted by amarin on Fri, 09/27/2019 - 18:45 Home Read more about REDUCE-IT: Residual Cardiovascular Risk in Statin-Treated Patients with Elevated Triglycerides: Now We Can REDUCE-IT!
Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients Submitted by amarin on Wed, 09/25/2019 - 14:34 Home Read more about Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients
Cardiovascular risk reduction with icosapent ethyl. Submitted by amarin on Wed, 09/25/2019 - 14:26 Home Read more about Cardiovascular risk reduction with icosapent ethyl.
Amarin to Participate in the Cantor Global Healthcare Conference Submitted by amarin on Mon, 09/23/2019 - 20:15 Home Read more about Amarin to Participate in the Cantor Global Healthcare Conference
Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides Submitted by amarin on Sat, 09/21/2019 - 12:47 Home Read more about Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides
Reply to letters from Chan L-N and from Borghi C, Fogacci F, Cicero AFG Submitted by amarin on Thu, 09/19/2019 - 20:34 Home Read more about Reply to letters from Chan L-N and from Borghi C, Fogacci F, Cicero AFG
Reduction in First and Total Ischemic Events with Icosapent Ethyl Across Baseline Triglyceride Tertiles Submitted by amarin on Thu, 09/19/2019 - 20:14 Home Read more about Reduction in First and Total Ischemic Events with Icosapent Ethyl Across Baseline Triglyceride Tertiles
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins Submitted by amarin on Mon, 09/16/2019 - 10:00 Home Read more about National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins
